Research, harm reduction, and community insights on psilocybin, psychedelic wellness, and the evolving legal landscape.
Industry news: All posts·2026 therapy trends·Therapy cost·Common mistakes
Legal access: Legal updates·State legal status·Oregon vs Colorado access
Compare therapies: Psilocybin vs ketamine·Psilocybin vs MDMA vs ketamine·Medication screening·SSRIs·Lithium
On October 5, 2026, MAPS announced a partnership with the International Alliance of Psychedelic Therapy Practitioners to build "clinical and ethical standards." The release names no curriculum, no hours, no cost, and no credential — and it landed on the exact day FDA's comment window closed on the same question. Meanwhile the first peer-reviewed safety data out of Oregon suggests facilitators reported one of four serious adverse reactions.
A Psychedelics Today video title asks whether psychedelic higher education is ready. The documents underneath it answer: FDA spent 2026 asking who should legally be qualified to sit in a dosing room, and the training industry that grew up ahead of that decision has no outcome evidence at all. Here is what a $9,400 certificate actually buys.
Chacruna Institute just marked ten years of Indigenous-centred psychedelic advocacy. That lane has produced real federal wins for ayahuasca and, by GAO's count, exactly nothing for psilocybin. Here is what each track has actually delivered, and which one you can lawfully use today.
Psychedelics Today hosted a livestream on "community-led psychedelic media" on September 23, 2026. We could not watch it, so we did the other job: checking who funds the outlets covering psilocybin, and whether the evidence underneath the headlines holds up. Short version — the loudest claims rest on company press releases, one uncontrolled 30-person study, and an executive order that changed nothing about federal law.
The Chacruna Institute ran a free forum on September 23, 2026 called "Building Tripsafe Communities." It contained no data — but the work its speakers do does. Here is what the published record says about psilocybin harms, and about whether harm-reduction services demonstrably reduce them.
A promo for a $20 after-party in Silver Spring is not the story. The story is the hearing it followed: FDA's first broad public session on how a legal psilocybin medicine would actually be delivered, held while Compass Pathways races to finish a rolling NDA — and while a JAMA Psychiatry review says the trials underneath all of it are functionally unblinded.
At FDA's September 14, 2026 public hearing on psychedelics, a chronic-pain advocate argued that the non-drug parts of a session — touch, neuromodulation, physical therapy — are doing real work, and that pain deserves a seat at a table FDA has set for psychiatry. The argument is reasonable. The evidence base under it is one case report, three tiny trials, a null result against active placebo, and a mouse study.
A DoubleBlind Short put the question back in circulation: is natural psilocybin better than synthetic? The honest answer is that two lines of preclinical evidence say maybe, no human trial has ever tested it, and every FDA-track program runs on synthetic anyway.
Two years after the Complete Response Letter, the company formerly known as Lykos has resubmitted MDMA-assisted therapy for PTSD — and it did not run the new Phase 3 trial the FDA recommended. It is leaning on third-party data, a fresh safety study, and a friendlier regulatory climate instead.
Governor González-Colón signed EO 2026-037 to study whether Puerto Rico can host trials of ibogaine, psilocybin, and MDMA. Veterans are named first. The order does not legalize therapy or authorize routine clinical use.
In one week the VA launched a five-site COMP360 trial for veterans, FDA finalized psychedelic clinical-investigation guidance and set a September 14 hearing, and ICON hired Anthropic’s Claude for trial operations.
Psychiatrist Dr. Tracey Marks explains how a clinical psilocybin dose can quiet rumination, reopen a plasticity window, and why that is not the same thing as a take-home mushroom pill.
Johns Hopkins professor Matthew Johnson explains why a 30–40mg “heroic dose” of psilocybin can feel life-changing — and why the container around it matters more than the milligrams.
A 2026 Nature Communications study in psychedelic-naïve adults found measurable brain-network and white-matter changes lasting at least a month after a single 25mg psilocybin session.
From COMP360's Phase 3 milestone to Colorado's rapid scale-up and MDMA's FDA resubmission, these are the five psychedelic therapy developments worth tracking in 2026.
Legal psilocybin therapy in Oregon or Colorado costs $1,500–$3,500 per complete experience. Retreats abroad run $3,000–$8,000+. Here's exactly what drives cost, what's included, and how to reduce it.
Most problems in psilocybin therapy are preventable. Here are the seven most common mistakes — stopping SSRIs abruptly, skipping integration, choosing an unverified facilitator — and exactly what to do instead.
From sub-perceptual microdoses to high-dose sessions, dose strongly shapes outcomes. We break down the evidence by dose range and what it means for therapy and personal use.
Early studies suggest that auditory stimulation and psilocybin may each influence brain rhythms and plasticity. We look at what's known and what's speculative in the context of Alzheimer's and cognitive decline.
New regulations allow more service centers to open statewide, making legal psilocybin therapy accessible to thousands more residents.
A potent hybrid known for euphoric visuals and creative energy. Here's what cultivators and users are saying about this rising favorite.
Researchers find significant and lasting reductions in depression symptoms after just two guided psilocybin sessions.
Following voter approval, licensed psilocybin healing centers begin welcoming clients in Denver and Boulder.
A high-potency cubensis strain whose reputation outruns its lab numbers. We break down effects, dosage, and what makes APE unique.
As legal access expands, advocates push for insurance coverage. Here's where the conversation stands in 2026.